Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Unsold Rams May Be Less expensive Than You Suspect - 2From Specialist to Proficient Picture taker: Individual Triumphs
- 3Amateur's Manual for Venture Strategies for Tenderfoots
- 4Picking Your Next SUV: 4 Brands Offering Execution, Solace, and Wellbeing
- 5Doctor's orders? ‘Belly laugh at least two to five days a week'
- Find the Abilities Required for Advanced Advertising Position
- Humpback whale freed by rescuers in Baltic Sea has become stranded again
- Somaliland denies trading recognition with Israel for accepting Gazans
- Foot fossil discovery could reshape human evolutionary history
- IDF kills senior PIJ Gaza City Brigade cmdr. who infiltrated Kibbutz Nahal Oz on Oct. 7
- Quandoo to shut restaurant booking platform by end of 2026
- Instructions to Pick the Right Gold Speculation Procedure: Exploring the Market
- Electric Vehicles for Eco-Accommodating Driving
- Authorities arrest 7 bodyguards in connection with a Mexican mayor's assassination
